ClinicalTrials.gg
RecruitingNCT06280534XT1061Updated Feb 28, 2024

Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects

A Phase 1 interventional study of Test drug XT1061 capsules and placebo,Single dose group and Test drug XT1061 capsules and placebo,Multiple dosing group in Chronic Hepatitis b, sponsored by Xi'an Xintong Pharmaceutical Research Co.,Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Xi'an Xintong Pharmaceutical Research Co.,Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jul 2023, registered Jan 2024).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 378 studies in Hepatitis B, Chronic with a site in China — 91 open to participants now, 112 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
132nd of 274
128 · median 120
Started
2023
with 28 others
Phase 1
51 of 378
17 open now
Primary completion
2024-02
later than 3 of 111 live
Registered
281st of 378
by date

Among the 378 studies in Hepatitis B, Chronic with a site in China, this one is the 132nd largest by planned enrollment of the 274 interventional ones that give a count, is one of 29 that started in 2023, is one of 51 in phase 1, reaches primary completion later than 3 of the 111 other live ones, and was the 281st registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

91 of the 378 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 378 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

A Randomized, Double-Blind, Single-Center Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effects of Single and Multiple Doses of XT1061 in Healthy Subjects.

Read the detailed description

This trial is a randomized, double-blind, dose-escalation, placebo-controlled, single-center clinical study designed to evaluate the safety, tolerability, pharmacokinetic profile and metabolic conversion of XT1061 in healthy subjects with single and multiple administrations, as well as a study of the effect of food on pharmacokinetics.

03

Conditions studied

  • Chronic Hepatitis b

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily sign the before the trial, and fully understand the content, process and possible adverse effects of the trial;
  2. They are able to complete the study according to the requirements of the trial protocol;
  3. Subjects (including partners) are willing to have no pregnancy plan and voluntarily use effective measures within 6 months from screening to the last dose of study drug;
  4. Male and female subjects between the ages of 18 and 65 (including borderline values);
  5. Male subjects weighing not less than 50 kg and female subjects weighing not less than 45 kg. (BMI) = weight (kg)/height 2 (m2), BMI within the range of 18-28 kg/m2 (including the threshold value);
  6. Physical examination and vital signs are normal or abnormal without clinical significance.

Exclusion criteria

Exclusion Criteria:

  1. Allergy (multiple drug and food allergies);
  2. Those who smoked more than 5 cigarettes per day in the 3 months prior to the test;
  3. History of drug and/or alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
  4. Blood donation or significant blood loss (> 450 mL) within three months prior to taking study drug;
  5. taking any prescription drug, over-the-counter drug, any vitamin product, herbal remedy, or alcohol within 14 days prior to taking study drug;
  6. have taken a special diet (e.g., grapefruit, mango, dragon fruit, grape juice, orange juice, etc., rich in flavonoids or citrus glycosides), or have had strenuous physical activity, or any other factor that affects the absorption, distribution, metabolism, or excretion of the drug within 2 weeks prior to administration of the study drug;
  7. Those who have recently made significant changes in their dietary or exercise habits;
  8. have taken the study drug, or participated in a clinical trial of the drug within three months prior to taking the study drug;
  9. have dysphagia or a history of any gastrointestinal disorder that interferes with the absorption of the drug within 6 months prior to the trial;
  10. have any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastroduodenal ulcers
  11. abnormalities; >470ms (QTcF=QT/(RR)\^0.33); and
  12. Female subjects who are breastfeeding or recently preparing for pregnancy or have a positive serum pregnancy result during the screening period or during the course of the trial;
  13. Abnormal and clinically significant clinical laboratory tests, or other clinical findings within the 12 months prior to screening that indicate clinically significant disease of the following (including, but not limited to, gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular disease);
  14. Positive screening for any of the Surface Antigen, Antibody/Hepatitis C Core Antigen, Antigen/Antibody, or Syphilis Spirochete Antibody;
  15. Acute illness or concomitant medication from the screening phase until study drug administration;
  16. ingestion of chocolate, any caffeinated or xanthine-containing food or beverage 24 hours prior to study drug administration;
  17. A positive urine drug screen or a history of substance abuse or drug use within the past five years;
  18. serum ≤ 70 mL/min [formula: Ccr: (140 - age) × body weight (kg) / (0.818 × Scr) (μmol/L), female × 0.85].
  19. Those who have special dietary requirements and cannot eat the entire test meal. Or those who did not agree to comply with the drinking arrangements and postural restrictions during the trial;
  20. Subjects who, in the opinion of the investigator, have other factors that make them unsuitable for participation in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Single dose group

    Single doses of 12.5mg (Group 1), 25mg (Group 2), 37.5mg (Group 3), 62.5mg (Group 4, Group A), 125mg (Group 5), 250mg (Group 6), alternative groups (Groups 7-10, 400-800mg).

    Drug: Test drug XT1061 capsules and placebo,Single dose group

  • Experimental
    Multiple dosing group

    Multiple administrations of 125mg, 250mg (groups 11, 12) Select one or both groups.

    Drug: Test drug XT1061 capsules and placebo,Multiple dosing group

  • Experimental
    Food Impact Group

    62.5 mg (i.e., single dose Group 4)

    Drug: Test drug XT1061 capsules and placebo,Food Impact Group

Interventions

  • DrugTest drug XT1061 capsules and placebo,Single dose group

    Eight people took capsules of the test drug XT1061 and two people took a placebo.

  • DrugTest drug XT1061 capsules and placebo,Multiple dosing group

    D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.

  • DrugTest drug XT1061 capsules and placebo,Food Impact Group

    Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.

06

What researchers measure

Primary outcomes

  1. Treatment-related adverse events

    Number of participants who experienced treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: Day 7

  2. Cmax

    Cmax

    Time frame: Day 4

  3. Tmax

    Tmax

    Time frame: Day 4

  4. t1/2

    t1/2

    Time frame: Day 4

  5. AUC

    AUC

    Time frame: Day 4

  6. CL/F

    CL/F

    Time frame: Day 4

  7. Vz/F

    Vz/F

    Time frame: Day 4

  8. CLr/F

    CLr/F

    Time frame: Day 4

Secondary outcomes

  1. Ae0-72 h

    Ae0-72 h

    Time frame: Day 4

  2. Fe0-72 h

    Fe0-72 h

    Time frame: Day 4

  3. bioavailability

    geometric mean value ratio

    Time frame: Day 4

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Feb 2024, 7 months after the start.

Of 82 phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Feb 28, 2024
StartActual
Jul 18, 2023
Primary completionEst.
Feb 29, 2024
CompletionEst.
Mar 31, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06280534
Lead sponsor
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Jul 18, 2023
Primary completion
Feb 29, 2024 (estimated)
Completion
Mar 31, 2024 (estimated)
Last update
Feb 28, 2024

Study contacts

Ding Yanhua, 硕士
Contact
1023307193@qq.com
18743062721

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion